Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial

Abstract

Aims/hypothesis: We evaluated in a double-blind study the effect of early treatment with the immunomodulatory drug fusidin in patients with newly diagnosed type 1 diabetes mellitus. Methods: Twenty-eight adults with newly diagnosed type 1 diabetes were included in the study. The patients were randomly assigned (computergenerated random number sequence) to two experimental groups. Patients allocated to the fusidin (FUS) group (n=15) received sodium fusidate (fusidin; 500 mg orally three times daily for 4 weeks). Subsequently the drug was given at the same dose and scheduled for two consecutive weeks a month followed by 2 weeks a month without the drug for 20 weeks. Subjects allocated to the placebo (PCB) group (n=13) received placebo according to the same schedule and conditions described for sodium fusidate in the FUS group. All patients received a diet adjusted to their age and BMI, and intensive insulin therapy. Results: There were no statistically significant differences between the FUS and PCB groups in beta cell function, evaluated by basal and glucagon-stimulated C-peptide values during the follow-up (24 and 48 weeks). There was also no difference between the two groups in insulin requirement after 48 weeks (0.4± 0.2 and 0.4±0.2 U/kg body weight for the FUS and PCB groups, respectively). Antibody titres, including insulin autoantibodies, were similar in the two groups during the follow-up. Conclusions/interpretation: Early treatment of newly diagnosed type 1 diabetes patients with intermittently administered fusidin failed to influence the natural course of the disease.

Relationship Between BMI and Age at Diagnosis of Type 1 Diabetes in a Mediterranean Area in the Period of 1990–2004

“…To our knowledge, this is the first study in a large cohort of a Mediterranean National Registry for new cases of type 1 diabetes in which the accelerator hypothesis is tested. Our results did not fit with the hypothesis and point to the heterogeneity of the disease in different populations (14,15). Accordingly, in a recent study including children who were either from the U.K. or originally from the south of Asia, Porter et al did not confirm the accelerator hypothesis (9).…”

The Safety Record of Fusidic Acid in Non-US Markets: A Focus on Skin Infections

“…The majority of these studies (n 5 80) were open label (78%). There were 13 blinded (single or double) studies [7][8][9][10][11][12][13][14][15][16][17][18][19] and 21 randomized trials, 12 of which were controlled, 5 with placebos [10,16,17,20,21]. One study, by Goncalves and Thorn [22], accounted for the majority (n 5 14,672) of exposures.…”

The Metabolic Functional Feature of Gut Microbiota in Mongolian Patients with Type 2 Diabetes

“…In an animal experiment, Fusidin could ameliorate the course of diabetes (Nicoletti F et al 2000). Although there are some other studies showed different result about the antibiotic improving diabetes (Conget I et al 2005), it is worth to do more in-depth study to uncover the function of that to regulate diabetes. 3-Hydroxyphenylacetic acid is an intermediate metabolite of quercetin metabolized by intestinal microbiome (Zabela V et al 2020), and lots of studies proved that quercetin has a function to treat T2D (Dhanya R. 2022).…”